D. Christopher Ohly
Partner
Schiff Hardin LLP
D. Christopher Ohly is a partner with Schiff Hardin LLP, resident in the firm's Washington, D.C. office. He has been a lawyer for more than 35 years. He has tried a large number of cases in a number of federal and state courts and regulatory agencies.
With extensive background in other litigation that provides him with insights into business management, securities litigation and valuation, Mr. Ohly now concentrates his practice in complex intellectual property matters, especially Hatch-Waxman generic pharmaceutical litigation. He has advised and participated in all aspects of litigation, serving as lead counsel for several generic manufacturers since 1999, in cases involving a number of small molecules.
Mr. Ohly is involved in his firm's life sciences practice, with ever increasing attention to representation of biologic therapeutics and the businesses involved in their development and marketing.
Mr. Ohly has long followed the development of biologics legislation and regulations in the United States, Europe and elsewhere, attending at one of the first on the matter, sponsored by NIST and the NY Academy of Sciences as an FDA Public Workshop, in December 2005, "Follow-on Biologics Workshop: Scientific Issues in Assessing the Similarity of Follow-on Protein Products." He recently attended the FDA’s most recent public hearing, on the creation of an "Approval Pathway for Biosimilar and Interchangeable Biological Products," in November 2010.
Along with his partners, Mr. Ohly has authored a number of peer-reviewed articles concerning biologics and other patent-related matters. One of his articles was recently published by the Oxford University Journal of Intellectual Property Law and Practice, "There Is No Orange Book: The Coming Wave of Biological Therapeutics." A forthcoming article in the Journal of Generic Medicines, to be published this Summer, will be entitled "Evergreening Biologics." Mr. Ohly has been a frequent speaker at conferences on Hatch-Waxman matters, including recent demonstrations on "The Inventor: Tackling Infringement by Effectively Describing the Development History and Background of the Patented Product - Cross Examination of the Inventor," and a presentation before the AIPLA’s Spring 2010 meeting, entitled “Hatch-Waxman: Prescriptions for Innovative and Inexpensive Medicines - The Generic Perspective."
With extensive background in other litigation that provides him with insights into business management, securities litigation and valuation, Mr. Ohly now concentrates his practice in complex intellectual property matters, especially Hatch-Waxman generic pharmaceutical litigation. He has advised and participated in all aspects of litigation, serving as lead counsel for several generic manufacturers since 1999, in cases involving a number of small molecules.
Mr. Ohly is involved in his firm's life sciences practice, with ever increasing attention to representation of biologic therapeutics and the businesses involved in their development and marketing.
Mr. Ohly has long followed the development of biologics legislation and regulations in the United States, Europe and elsewhere, attending at one of the first on the matter, sponsored by NIST and the NY Academy of Sciences as an FDA Public Workshop, in December 2005, "Follow-on Biologics Workshop: Scientific Issues in Assessing the Similarity of Follow-on Protein Products." He recently attended the FDA’s most recent public hearing, on the creation of an "Approval Pathway for Biosimilar and Interchangeable Biological Products," in November 2010.
Along with his partners, Mr. Ohly has authored a number of peer-reviewed articles concerning biologics and other patent-related matters. One of his articles was recently published by the Oxford University Journal of Intellectual Property Law and Practice, "There Is No Orange Book: The Coming Wave of Biological Therapeutics." A forthcoming article in the Journal of Generic Medicines, to be published this Summer, will be entitled "Evergreening Biologics." Mr. Ohly has been a frequent speaker at conferences on Hatch-Waxman matters, including recent demonstrations on "The Inventor: Tackling Infringement by Effectively Describing the Development History and Background of the Patented Product - Cross Examination of the Inventor," and a presentation before the AIPLA’s Spring 2010 meeting, entitled “Hatch-Waxman: Prescriptions for Innovative and Inexpensive Medicines - The Generic Perspective."
Webinars Conducted By D. Christopher Ohly
Content Disclaimer
Contents in our website are from external websites. Links to and content from external website are provided for the convenience of users. Biopractice.com takes no responsibility for the content of such links and websites.